Varex Imaging Corporation (VREX) witnessed a significant pre-market surge of 5.77% on Wednesday, following the release of its fourth-quarter earnings report and insights into the company's strategic growth initiatives.
The medical imaging technology provider reported strong performance in the industrial segment during the fourth quarter, with revenues exceeding guidance. Additionally, the company expressed optimism about the potential growth in medical imaging demand in China, positioning itself to capitalize on the market's recovery.
Notably, Varex Imaging is investing in photon counting technologies, which are expected to be a significant revenue growth driver. The company aims to generate $150 million in annual revenue from this advanced technology by fiscal 2029. Furthermore, Varex is expanding its product portfolio into premium applications such as surgery, oncology, and cardiology, fueling future growth prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。